Form D · Other
Tassili Life Science Corp.
Toronto, A6 · CIK 0001806185
Offering snapshot reported Mar 11, 2020 · SEC filing
- Reported sold
- $300K Offering amount: $300K
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 21, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 11, 2020 | Initial | $300,211 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity, Debt, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-362494
Convertible Debentures bearing interest of 8% per annum, convertible into units or common shares of the Company subject to certain terms and conditions inconnection with a Go Public Transaction.
Convertible Debentures bearing interest of 8% per annum, convertible into units or common shares of the Company subject to certain terms and conditions in connection with a Go Public Transaction.
Source: Form D, filed Mar 11, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Maghsoud Dariani | Executive |
| Jonathan Gilbert | Director, Executive |
| Jonathan Held | Director, Executive |
| George Scorsis | Director |
Issuer details
Industry: Other (See others in industry)
Address:
366 Bay Street, Suite 200
Toronto, A6, M5H 4B2
Toronto, A6, M5H 4B2